Swedish biotech company Salipro Biotech AB has entered into a research collaboration with South Korea headquartered Daewoong Pharmaceutical Co.
Daewoong Pharmaceutical gains access to Salipro Biotech's expertise and Salipro® platform for stabilising challenging membrane proteins (e.g., GPCRs, ion channels, transporters). The collaboration will target a specific membrane protein to aid Daewoong's development of novel small molecule drugs.
Under the terms of this agreement, the collaboration will enable Daewoong Pharma to leverage Salipro Biotech´s expertise and proprietary platform to advance their drug discovery efforts in the development of novel therapeutic small molecules against a challenging membrane protein drug target.
Jens Frauenfeld, CEO of Salipro Biotech said, "This partnership is particularly significant as it marks our first collaboration with a partner in South Korea, underscoring the global application and versatility of our expertise and platform to make the undruggable druggable."
Seongsoo Park, CEO at Daewoong Pharmaceutical stated, "Collaborating with Salipro Biotech and accessing their Salipro® platform aligns with our goal to address complex drug targets. Salipro's expertise in membrane protein stabilisation will benefit our research for novel small molecule therapeutics, and we look forward to the results of our joint efforts."
